Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-05-12

Clinical Trial Update: Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy [Phase 2]

View source ↗

Summary

Phase 2 study updating the effect of Zometa on bone mineral density in prostate cancer patients undergoing androgen deprivation therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Zometa (Zoledronic acid)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-05-12